Skip to content
OpenCapital
Get started

Health Catalyst HCAT Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

IQVIA logo
IQVIAIQV
——

Other financials

Income statement

See full
Revenue$70.8M-10.9%
Gross profit$35.5M-2.1%
Operating income-$106.5M-428%
Net income-$111.0M-368%
EPS (diluted)-$1.53-337%

Balance sheet

See full
Cash & equivalents$59.9M-82.5%
Total debt$170.6M-57.6%
Total equity$138.1M-63.3%
Total assets$412.2M-53.8%

Cash flow

See full
Operating cash flow$18.5M+6,511%
CapEx$338.0K-49.6%
Free cash flow$18.2M+4,760%

Valuation

See full
Market cap$147.05M-43.6%
Enterprise value$257.76M-32.7%
P/S0.5×-0.3×

Profitability

See full
Gross margin49.9%+4.7pp
Operating margin-81.7%-127pp
Net margin-87.7%-138pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-103%-135pp
Debt / equity1.2×+0.2×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Health Catalyst in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Health Catalyst’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Health Catalyst (HCAT) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $6.99M in Q1 2026.
How has Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?
Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net decreased by 23.4% year-over-year, from $9.13M to $6.99M.
What is the long-term trend for Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Over 2 years (2023 to 2025), Health Catalyst's debt instrument, unamortized discount (premium) and debt issuance costs, net has grown at a 95.4% compound annual growth rate (CAGR), from $1.97M to $7.51M.